Castle Biosciences CSTL Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$12.83M-153% | -$24.16M-232% | -$12.24M-301% | -$9.47M-205% | -$5.07M+83.5% | ||
| $14.94M-64.8% | $40.77M+155% | $42.76M+218% | $42.49M+225% | $42.42M+232% | ||
| $44.49M-8.9% | $45.89M-8.8% | $45.93M-9.4% | $46.85M-7.6% | $48.82M-3.1% | ||
| -$5.58M— | -$6.34M— | —— | —— | —— | ||
| -$13.17M-197% | -$6.88M-154% | $165K-98.7% | $6.33M-56.6% | $13.6M-8.2% | ||
| $3.64M+557% | $2.14M+1,010% | $2.1M+162% | $353K-84.3% | -$796K-123% | ||
| $5.67M+270% | $3.1M+171% | $2.53M+420% | -$1.03M— | -$3.34M— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$342K— | -$404K— | —— | ||
| —— | —— | $3.88M— | $315K— | -$870K— | ||
| -$921K+41.2% | -$1.28M+1.1% | -$1.49M— | -$1.73M— | -$1.57M— | ||
| $48.25M-26.5% | $64.35M-0.8% | $61.78M— | $62.49M— | $65.67M— | ||
| $43.74M+82.9% | $36.02M+27.2% | $36.4M+48.3% | $27.95M+35.5% | $23.91M+23.0% | ||
| $195.42M+1.0% | $188.71M-8.3% | $198.63M-5.8% | $185.37M-14.1% | $193.41M-12.0% | ||
| —— | —— | —— | —— | $0— | ||
| $43K+95.5% | $45K+150% | $47K+236% | $32K+167% | $22K+69.2% | ||
| —— | —— | —— | —— | $5.57M— | ||
| —— | $2.11M— | $1.59M— | $1.06M— | $528.5K— | ||
| —— | —— | —— | —— | —— | ||
| $2.51M+27.4% | $2.21M+9.4% | $487K-71.6% | $1.98M+1,154% | $1.97M+724% | ||
| $113K+29.9% | $115K+18.6% | $114K+6.5% | $107K-10.1% | $87K-39.2% | ||
| $15.74M+45.7% | $11.66M+33.0% | $10.67M+66.7% | $10.78M+101% | $10.8M+104% | ||
| -$10.54M— | -$7.06M— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $3.24M-49.6% | $4.22M-36.9% | $5.12M-23.7% | $5.87M-11.5% | $6.42M+7.7% | ||
| —— | —— | —— | —— | -$1.01M-827% | ||
| —— | —— | —— | —— | —— | ||
| -$921K+41.2% | -$1.28M+1.1% | -$1.49M— | -$1.73M— | -$1.57M— | ||
| -$1.32M+5.8% | -$1.37M-3.8% | -$1.34M— | -$1.31M— | -$1.4M— | ||
| —— | —— | —— | —— | —— | ||
| $883K+294% | $391K+249% | -$218K— | -$81K— | -$454K— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$342K— | -$404K— | —— | ||
| —— | —— | —— | —— | $5.57M— | ||
| —— | —— | —— | —— | $0— | ||
| $43K+95.5% | $45K+150% | $47K+236% | $32K+167% | $22K+69.2% | ||
| $113K+29.9% | $115K+18.6% | $114K+6.5% | $107K-10.1% | $87K-39.2% | ||
| $2.71M-5.2% | $2.42M-19.0% | $2.35M-22.1% | $2.71M-2.0% | $2.86M+1.6% | ||
| —— | —— | —— | —— | —— | ||
| -$921K+41.2% | -$1.28M+1.1% | -$1.49M— | -$1.73M— | -$1.57M— | ||
| —— | —— | —— | $171K+3.0% | $262K— | ||
| $4.52M-89.2% | $28.33M-22.5% | $25.38M— | $34.54M— | $41.75M— | ||
| $4.52M-89.2% | $28.33M-22.5% | $25.38M— | $34.54M— | $41.75M— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Castle Biosciences generate?
- Castle Biosciences (CSTL) generated $48.3M in operating cash flow over the trailing twelve months.
- What is Castle Biosciences's free cash flow?
- After $43.7M of capital expenditures, Castle Biosciences's free cash flow was $4.5M over the trailing twelve months, down 89.2% year over year.
- Where does Castle Biosciences's cash flow data come from?
- Every line is extracted from Castle Biosciences's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
